Israel is considered by many to be the next frontier for the cannabis industry and this is a market that we have been highly focused on. By having an ideal climate for the cultivation of cannabis and a close proximity to the European Union (EU), the Israeli cannabis market represents an attractive cannabis opportunity.
During the last few years, we have been monitoring the advancement of the Israeli cannabis industry and find the market to be a high-growth opportunity that is not saturated. Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) has been highly focused on the Israeli cannabis market and is working to gain a first-mover advantage.
In November, we published a deep dive article that covered the Israeli cannabis company as well as a business opportunity report that is focused on the operation. Today, we issued an update on Isracann and this comes after the company reported an important milestone. As we head into the end of the year, we believe that Isracann is well positioned for growth and will continue to follow the opportunity.
Isracann Reports Major Milestones for the Business
Last week, Isracann Biosciences had its architectural, agronomic and security plans approved by the Israeli Land Authority, which is responsible for overseeing the utilization of national land reserves, and this represents an important step in the process to capitalizing on a burgeoning market. The approval includes detailed architectural plans encompassing the land, facility layout, and this represents an important advancement in the process.
Earlier this year, Isracann formed relationships with a number of professional consultants that understand the landscape of the Israeli cannabis industry and we have been favorable on this aspect of the story. Through these strategic relationships, the company has been able to expedite the submission process and we find this to be significant. Isracann has been working tirelessly to advance the operation and we find this to be of importance due to the company’s ability to gain a first-mover advantage on Israel’s cannabis export market.
When looking at the partners that assisted with the operation, there is a lot to be excited about. The company formed relationships with some of the world’s top experts for architecture (used AgroPlan Ltd.), for security (used the A.R. Factor Group), and for agronomists (used LinC by Growing Smart Ltd.). Isracann’s consultants told the management team that the application fully complies with the regulatory framework and we will monitor this aspect of the story.
Going forward, the management team expects to make a timely announcement as it relates to the breaking of ground at the proposed 230,000 sq. ft purpose-built facility. Once Isracann has been granted the necessary permits and approvals to break ground, we expect to see this become a primary focus for the business and are bullish on the amount of revenue that can be generated from the facility.
One of the most important aspects of the Isracann story is related to the strength of the management team and this is an area that continues to be in focus. Last week, Isracann appointed Matt Chatterton as Vice President of Operations and we are favorable on the addition. With more than 15 years of experience in the design, development and execution across a variety of projects and manufacturing operations, Matt represents a strategic addition to the team, and we are favorable on the expertise that he adds to the operation.
We expect Matt to prove to be an important addition to the team. His expertise includes project management, facility management, logistics, supply side processes and procedures at a number of international manufacturing operations in Canada, China, Bulgaria, the Philippines and now in Israel. His role at Isracann includes facility oversight of the design, build out, and operational implementation, commencing with the inaugural cultivation farm and will eventually encompass manufacturing, formulation, and distribution management.
Working to Capitalize on Undersupplied Cannabis Markets
According to the management team, the operation is advancing on schedule and we will be monitoring the way the story evolves from here. Going forward, we expect the addition of Mr. Chatteron to play a key role in the creation of a sustainable business that is focused on creating value for all parties involved.
Earlier this year, we started covering Isracann and have been impressed with the way the fundamental story has been advancing. Once the company completes the construction of a state-of-the-art cultivation facility, the business will be able to capitalize on the European Union (EU) export opportunity and we expect the market to be a major revenue generator. When looking at Isracann, there is a lot to be excited about and we want to highlight some of the most important aspects of the operation:
- Israel’s first pure play cannabis firm to list in Canada giving it first mover advantage.
- Focused on becoming a premiere, low-cost cannabis producer.
- Fully funded to execute on 230,000 sq. ft. of hybrid greenhouse to IMC-GAP/GSP standards
- Targeting undersupplied domestic demand
- With the Israeli export framework in place and expected to be live by mid-2020, Isracann plans to be positioned to supply the cannabis market in the EU
We expect 2020 to be a banner year for the Israeli cannabis industry as well as Isracann Biosciences. We believe that Isracann has substantial potential catalysts for growth and will monitor how the management team is able to gain a first mover advantage on the domestic and the export opportunity.
An Emerging Opportunity to be Watching
We see several potential catalysts for Isracann in the coming quarters as the company begins to scale operations and the regulatory climate improves. We have been watching both the European and Israeli markets mature and expect to see an inflection point to the upside in 2020.
We believe that Isracann Biosciences is positioning itself to capitalize on a premier global cannabis market and this is an opportunity that we will be watching closely as it develops. To learn more about the Israeli cannabis company, please email email@example.com to be added to our distribution list.
Pursuant to an agreement between StoneBridge Partners LLC and Isracann Biosciences (IPOT) we have been hired for a period of 365 days beginning December 9, 2018 and ending January 9, 2020 to publicly disseminate information about (IPOT) including on the Website and other media including Facebook and Twitter. We are being paid $10,000 per month (IPOT) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (IPOT), which we purchased in the open market. We plan to sell the “ZERO” shares of (IPOT) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (IPOT) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.